» Articles » PMID: 26936044

Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers

Overview
Specialty Pharmacology
Date 2016 Mar 4
PMID 26936044
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A simple method to predict drug-drug interactions mediated by cytochrome P450 enzymes (CYPs) on the basis of in vivo data has been previously applied for several CYP isoforms but not for CYP1A2. The objective of this study was to extend this method to drug interactions caused by CYP1A2 inhibitors and inducers.

Methods: First, initial estimates of the model parameters were obtained using data from the literature. Then, an external validation of these initial estimates was performed by comparing model-based predicted area under the concentration-time curve (AUC) ratios with observations not used in the initial estimation. Third, refined estimates of the model parameters were obtained by Bayesian orthogonal regression using Winbugs software, and predicted AUC ratios were compared with all available observations. Finally, predicted AUC ratios for all possible substrates-inhibitors and substrates-inducers were computed.

Results: A total of 100 AUC ratios were retrieved from the literature. Model parameters were estimated for 19 CYP1A2 substrate drugs, 26 inhibitors and seven inducers, including tobacco smoking. In the external validation, the mean prediction error of the AUC ratios was -0.22, while the mean absolute error was 0.97 (37 %). After the Bayesian estimation step, the mean prediction error was 0.11, while the mean absolute error was 0.43 (22 %). The AUC ratios for 625 possible interactions were computed.

Conclusion: This analysis provides insights into the interaction profiles of drugs poorly studied so far and can help to identify and manage significant interactions in clinical practice. Those results are now available to the community via a web tool ( http://www.ddi-predictor.org ).

Citing Articles

Integrated Use of In Vitro and In Vivo Information for Comprehensive Prediction of Drug Interactions Due to Inhibition of Multiple CYP Isoenzymes.

Hozuki S, Yoshioka H, Asano S, Nakamura M, Koh S, Shibata Y Clin Pharmacokinet. 2023; 62(6):849-860.

PMID: 37076696 DOI: 10.1007/s40262-023-01234-6.


Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach.

Tuloup V, Goutelle S, Tod M, Bourguignon L Clin Pharmacokinet. 2023; 62(2):307-319.

PMID: 36631686 DOI: 10.1007/s40262-022-01205-3.


Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction.

Di Paolo V, Ferrari F, Poggesi I, Quintieri L Clin Pharmacokinet. 2022; 61(9):1297-1306.

PMID: 35857278 DOI: 10.1007/s40262-022-01153-y.


Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study.

Ray J, Cheng S, Tsan K, Hussain H, Stark R, Matharu M Front Neurol. 2022; 13:842082.

PMID: 35356451 PMC: 8959588. DOI: 10.3389/fneur.2022.842082.


In vitro evaluation of the inhibition potential of echinacoside on human cytochrome P450 isozymes.

Wu Y, Qiao A, Lin S, Chen L BMC Complement Med Ther. 2022; 22(1):46.

PMID: 35180866 PMC: 8857812. DOI: 10.1186/s12906-022-03517-0.


References
1.
May D, Jarboe C, VanBakel A, Williams W . Effects of cimetidine on caffeine disposition in smokers and nonsmokers. Clin Pharmacol Ther. 1982; 31(5):656-61. DOI: 10.1038/clpt.1982.91. View

2.
Jeppesen U, Gram L, Vistisen K, Loft S, Poulsen H, Brosen K . Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996; 51(1):73-8. DOI: 10.1007/s002280050163. View

3.
Larsen J, Hansen L, Spigset O, Brosen K . Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Eur J Clin Pharmacol. 1999; 55(5):375-82. DOI: 10.1007/s002280050643. View

4.
Lahu G, Nassr N, Herzog R, Elmlinger M, Ruth P, Hinder M . Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2010; 51(4):586-93. DOI: 10.1177/0091270010370590. View

5.
Labbe L, Abolfathi Z, Robitaille N, St-Maurice F, Gilbert M, Turgeon J . Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. Ther Drug Monit. 1999; 21(2):191-9. DOI: 10.1097/00007691-199904000-00009. View